spacer
home > ict > winter 2018 > a valued perspective
PUBLICATIONS
International Clinical Trials

A Valued Perspective

Acceleration of the integration of mobile health (mHealth) technologies into clinical trial operations is expected to be the catalyst for the adoption of disruptive research platforms with capabilities to overcome barriers in both clinically mature and emerging markets. While mHealth applications of smart devices, wearable biometric sensors, and telemedicine enable health monitoring, data collection, and patient communications have been around for some time. Despite this, their widespread use in clinical research should still be considered in its infancy. We continue to see the fast development of integrated mHealth platforms that have the potential to turn the traditional research model on its head taking studies to patients rather than bringing patients into site-based studies. Powered by Big Data and connected across patients, researchers, and caregivers, emerging mHealth platforms will expand research participation, reduce costs, and integrate research with treatment in new models of personalised medicine based on real-world evidence.

The mHealth Disruption Four foundational trends are driving 21st century biomedical research:

  • Globalisation is expanding drug development into the emerging markets of Africa, Asia, and Latin America
  • Big Data is being harnessed to understand disease impacts at the population level and support evidence-based medical practice
  • Real-world evaluation is extending the continuum from traditional randomised clinical trials to new research models that assess real-world outcomes
  • Personalised medicine is advancing with targeted therapies tailored to smaller populations and the growth of patientcentric research

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
David Blackman has responsibility for aligning technology strategies and innovations with PPDs evolving business needs. Within his role, David is responsible for creating and developing differentiating business capabilities together with partners and clients to accelerate clinical trial research. He has a strong passion for the design and implementation of mobile health and digital technologies solutions within clinical research. A graduate of the University of Johannesburg, South Africa, he combines more than 20 years of technological experience in development, process, and technology innovations with his commitment to implementing cutting-edge technologies as a platform to advance innovative technology solutions in clinical trials worldwide. He holds two patents and two patent applications for technology innovations.
spacer
David Blackman
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PPMA Group Industry Awards 2018 Call for Entries Deadline 31st July

The PPMA Group Industry Awards, which recognise manufacturing excellence, technical innovation, entrepreneurship as well as outstanding achievement and contribution to the industry, will this year take place at a new venue the Hilton Birmingham Metropole Hotel at the NEC - on the 25th September 2018.
More info >>

White Papers

Crossing the Blood Brain Barrier (BBB): Which Route to Take?

Aptar Pharma

Aptar Pharma recently hosted an expert panel/roundtable on the various approaches to treating central nervous system (CNS) diseases. This international scientific forum was held in Paris, France on December 5th, 2014. The roundtable was organized to explore and exchange views on the challenges, approaches and opportunities that exist with regard to effectively crossing the blood brain barrier (BBB) and successfully treating a host of CNS diseases.
More info >>

 
Industry Events

Synthetic Biology Congress

8-9 November 2018, London, UK

Oxford Global is proud to present its Synthetic Biology Congress taking place on 8-9 November 2018 in London. As part of our Genomics and Synthetic Biology UK series, our congress will bring together Over 600 delegates representing internationally renowned research & academic institutions, clinical research institutions and pharmaceutical companies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement